Telehealth & Digital Health

Early data reveals a novel immunotherapy, STC-1010, may activate the immune system against a common, treatment-resistant form of colorectal cancer.

After a major pipeline pivot, Keros Therapeutics faces investors with a new lead drug, a fortified balance sheet, and a high-stakes strategy to prove.

A landmark study finds nearly half of Americans use OTC drugs weekly, revealing a quiet revolution in self-care that challenges current healthcare policy.

New head-to-head study results for POSLUMA PET imaging could redefine diagnostic clarity for prostate cancer, promising earlier and more precise detection.

A new tool, SpecKit, built on Form.io's platform, aims to solve a critical bottleneck in healthcare by simplifying the creation of FHIR test data.

In a landmark $9.9 billion all-cash deal, Danaher will acquire Masimo, aiming to dominate the patient monitoring market from hospital to home.

Landmark study in JAMA Neurology shows BRIUMVI offers near-zero relapse rates and stable disability, reshaping long-term multiple sclerosis treatment.

With its burn treatment gaining traction and a pivotal wound care drug in late-stage trials, MediWound prepares to make its case to Wall Street.

NRx Pharmaceuticals gets a green light from the FDA to seek broader approval for its ketamine drug, NRX-100, using a novel real-world evidence approach.

A new health tech company has assembled a star-studded scientific board to back its AI-powered dementia prevention app. But can it deliver on its promise?

With a new national certification, Orange Coast Medical Center is raising the bar for heart patient recovery, backed by data showing dramatic life-saving results.

Nearly half of UK couples struggle with hearing loss, eroding intimacy. A new campaign reveals why a hearing check may be more romantic than any gift.

Atlanta's World Neuroscience Day Conference returns to explore the brain-heart connection, demystify clinical trials, and empower a growing community.

Acurx Pharmaceuticals preps for pivotal Phase 3 trials for its novel C. diff antibiotic, Ibezapolstat, with global regulatory alignment in place.

A landmark trial shows Retevmo significantly cuts cancer recurrence in early-stage patients, pushing for a new standard of care and early genetic testing.

CenterWell's major acquisition of MaxHealth adds 82 clinics and 120,000 patients, deepening its hold on Florida's value-based senior care sector.

Alto Neuroscience completes enrollment for a trial of its skin patch drug, ALTO-101, offering new hope for the millions battling cognitive decline in schizophrenia.

Aktiia's Hilo adds sleep and step tracking to its validated blood pressure monitor, promising a holistic view of heart health in a competitive market.

Aethlon Medical advances its Hemopurifier for oncology and Long COVID, but a shrinking cash reserve and rising quarterly loss test its lean science strategy.

Clinical-stage biotech BioVie announces its novel anti-inflammatory drug, bezisterim, will be featured at a key psychiatric conference for its potential.